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Nuclear Inclusions in Glutamine Minireview
Repeat Disorders: Are They Pernicious,
Coincidental, or Beneficial?
toxic ªgain of functionº in these disorders? The first
insight emerged by analysis of mice that overexpress a
transgene containing the promoter and first exon of HD
and 115±150 CAG repeats. These mice developed a
progressive neurological phenotype including weight
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loss, seizures, involuntary movements, brain atrophy,
and premature death. The most conspicuous neuronal
abnormality is the presence of a single amorphous intra-
Expansions of CAG triplets within the coding regions of
nuclear inclusion, termed NII, in cortical and striatal neu-
target genes are the cause of a variety of autosomal
rons that are decorated by antibodies to ubiquitin and
dominant neurodegenerative disorders, including Hun-
the N terminus of huntingtin (htt) (Davies et al., 1997).
tington's disease (HD), several spinocerebellar ataxias Similarly, NIIs have been documented in cerebellar
(SCAs), dentatorubralpallidoluysian atrophy (DRPLA), Purkinje cells of transgenic mice overexpressing an ex-
and X-linked spinocerebellar muscular atrophy (SBMA) panded variant of the ataxin-1 gene that causes spino-
(reviewed in Paulson and Fishbeck, 1997). HD and cerebellar ataxia, type 1 (SCA1) (Skinner et al., 1997).
DRPLA are manifested by unusual movements and de- These mice exhibit severe ataxia and alterations in Pur-
mentia, and SCA1 and SCA3 (commonly termed Ma- kinje cell nuclear and dendritic morphology, manifesta-
chado-Joseph disease) are characterized by ataxia and tions that long precede cell death (Burright et al., 1995).
incoordination. These disorders are characterized by an Moreover, expression of polyglutamines elicits patho-
unusual patterns of paternal inheritance, termed genetic genic properties independent of the polypeptide back-
ªanticipation.º In successive generations of a pedigree, bone in which they reside, as amply demonstrated by
the severity of disease increases and age-of-onset of studies in which targeting of 146 CAG repeats into the
clinical symptoms decreases. Remarkably, the age-of- third exon of murine Hprt gene gave rise to mice that
onset is inversely correlated with the length of the ªab- developed ataxia, seizures, and premature death. NIIs
normalº CAG expansion. Although the target genes have were also conspicuous in neuronal nuclei of these mice
little homology, except in the highly polymorphic CAG (Ordway et al., 1997). Importantly, NIIs are present in
tract, pathogenicity is invariably provoked when the dis- the brains of patients with CAG expansion disorders;
ease chromosome expands to a ªthresholdº of between they are a common feature in neurons of the cortex and
35±40 CAG repeats. Curiously, despite the widespread striatum of juvenile-onset HD cases but are absent in
expression of each polypeptide, each disorder is char- regions of the brain unaffected by the disease (DiFiglia
acterized by a highly stereotypical pattern of degenera- et al., 1997). Antibodies to ataxin-1 and ubiquitin detect
tion of selected subpopulations of neurons. For exam- NIIs in the nucleas pontis centralis, a region prominently
ple, the chorea and dementia in HD are related to the affected in SCA1, but fail to detect inclusions in brain
degeneration of subsets of striatal and cortical neurons. regions unaffected by disease (Skinner et al., 1997). Col-
In SCA1, SCA3, and DRPLA, a variety of cell populations lectively, the presence of NIIs in vulnerable neurons of
undergo degeneration, particularly in the cerebellum, the human disorders and their association with the clini-
while in SBMA spinal and brainstem motor neurons are cal and pathological lesions in transgenic mice have led
most vulnerable. to the widely held view that these abnormal depositions
Nuclear Inclusions and Disease: Correlations are toxic and, hence, pathogenic. That popular notion
The mechanisms by which specific polypeptides with will certainly be shaken by two elegant, and entirely
extranumerary glutamine residues cause neurodegener- unexpected, observations reported in this issue of Cell
ation and selective neuronal vulnerability in each disor- by Orr, Zoghbi, and colleagues (Klement et al., 1998)
der have been the subject of intensive investigation. and Greenberg and colleagues (Saudou et al., 1998),
Evidence has accrued supporting the notion that mutant which suggest that the NIIs may not be so pernicious,
polypeptides with glutamine expansions cause disease after all.
by a ªgain of toxic functionº rather than simply by loss Requirements for Pathogenicity
of activity (haploinsufficiency), including the following Extending their earlier studies of mutant ataxin-1 mice,
observations: (1) individuals with deletions of the andro- Orr and colleagues (Klement et al., 1998) now examine
gen receptor and huntingtin genes, expanded in SBMA the importance of nuclear localization and aggregation
and HD, respectively, do not exhibit clinical or neuro- of mutant ataxin-1 in pathogenesis. Ataxin-1 contains a
pathological phenotypes associated with these disor- sequence similar to a consensus monopartite nuclear
ders; (2) individuals homozygous for the HD mutation localization signal (NLS) and, at steady-state, is pres-
have a disease no more severe than individuals with a ent both in the nuclear and cytoplasmic compartments
single mutant allele; (3) in HD, levels of polypeptides in Purkinje cells. A chimera consisting of a segment
encoded by the normal and mutant alleles are identical of ataxin-1 containing the putative NLS, fused to the
(Trottier et al., 1995); and (4) mice with a heterozygous cytoplasmic protein chicken muscle pyruvate kinase
deletion of HD or Sca1 do not show behavioral or neuro- (CMPK), accumulates in the nucleus of transfected
pathological alterations (Duyao et al., 1995; Matilla et COS-1 cells. A similar chimera with an inactivating muta-
al., 1998). tion (K772T) of the putative NLS is redistributed to the
cytoplasm. In transgenic mice, human ataxin-1 with 82What are the biochemical substrates involved in the
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glutamines is predominantly localized to the nucleus of gone to considerable length to clarify the mechanisms
by which mutant htt induces neurodegeneration. ThePurkinje cells, but in contrast, ataxin-1 containing both
82 glutamines and the K772T mutation revealed nearly experiments are compelling: expression of truncated
htt with a nuclear export signal (NES) exhibited neitherexclusive cytoplasmic localization. More importantly,
despite comparable levels of transgene expression, inclusions in the nucleus or cytoplasm, nor neurodegen-
eration. Forced retention of the NES-containing poly-mice expressing ataxin-1 with 82 glutamines and the
K772T substitution exhibited neither ataxia, NIIs, nor peptide in the nucleus by the addition of leptomycin B,
an inhibitor of nuclear export, fully restored the abilityobvious histopathological alterations in Purkinje cells
as found in transgenic mice expressing the same of mutant htt to form inclusions. Are the nuclear aggre-
gates toxic, per se? It seems unlikely. Supporting stud-ataxin-1 with a wild-type NLS. Thus, absence of disease
in mice expressing mutant ataxin-1 with a defective NLS ies in HEK293 cells (Hackam et al., 1998), Saudou et
al. report that in hippocampal and striatal neurons, theappears to be due to the failure of the molecule to enter
the nucleus. percentage of neurons with detectable inclusions in-
creased as the length of the N-terminal htt fragmentInitial yeast two-hybrid interaction screens revealed
the presence of a self-association domain in ataxin-1. decreased. However, and most remarkably, the percent-
age of striatal neurons undergoing apoptosis remainedIn what might be imagined as a stroke of serependipity,
Klement et al. demonstrate that transient expression of constant irrespective of the length of mutant htt or the
percentage of neurons with inclusions, thus demonstrat-a mutant ataxin-1 with 77 glutamines that lacked part
of the interaction domain (ataxin-1[77]D) entered the ing a clear lack of correlation between polyglutamine-
induced apoptosis and NII formation.nucleus of transfected cells but did not form aggregates.
Moreover, ataxin-1[77]D polypeptides encoded by a If the nuclear aggregates are innocent bystanders, as
the data would suggest, then why do they occur in thetransgene targeted to Purkinje cells was predominantly
nuclear, but light and immunoelectron microscopic ap- first place? Although the jury is still out on this one, a
clue emerges from a clever experiment by Saudou etproaches did not detect the presence of nuclear aggre-
gates. Surprisingly, the ataxin-1[77]D mice developed al. Using the consistent observation that nuclear inclu-
sions in patients, mice, or cultured cells expressing mu-Purkinje cell pathology, including cytosolic vacuoliza-
tion and dendritic pruning that preceeded ataxia. The tant htt are immunoreactive with antibodies to ubiquitin,
Saudou et al. tested the notion that blocking ubiquitina-temporal course of the development of histological le-
sions and neurological disease was nearly indistinguish- tion of htt might inhibit formation of intranuclear inclu-
sions. As predicted, coexpression of an htt fragmentable to that of mice expressing ataxin-1 with 82 gluta-
mines. Thus, the formation of nuclear microscopic with polyglutamine expansions along with a dominant
interfering mutant of the ubiquitin-conjugating enzymeaggregates is not required for the initiation of mutant
ataxin-1-mediated pathogenesis in transgenic mice. It Cdc34p (hCdc34p [CL→S]) resulted in a dramatic de-
crease in the number of nuclear inclusions. Surprisingly,is still conceivable, however, that the nuclear aggregates
may have a role in disease progression. the rate of cell death in these cultures was markedly
accelerated relative to cultures expressing the mutantIf nuclear aggregates don't initiate disease, then what
does? The answer to that formidable question is far from htt fragment alone. A provocative suggestion emerging
from these experiments is that NIIs might represent aclear, but a welcome in vitro cellular model of neurode-
generation described by Greenberg and colleagues cellular strategy to inactivate toxic nuclear forms of htt
with expanded polyglutamines.(Saudou et al., 1998) promises to bear fruit in this re-
gard. In these studies, cultured striatal neurons were A Structural Basis for Nuclear Translocation
and Cell Specificity?transfected with cDNAs encoding wild-type or mutant
versions of huntingtin and scored for cell survival. Ex- Notwithstanding the significance of the reports by Kle-
ment et al. and Saudou et al., there remain significantpression of a truncated htt containing an expanded poly-
glutamine stretch led to the accumulation of large nu- lacunae in our understanding of the mechanism(s) that
regulate nuclear import and subsequent aggregation ofclear aggregates and ultimately to cell death. However,
the presence of nuclear inclusions was in no way pre- polypeptides with glutamine expansions. An equally
challenging problem relates to the mechanisms bydictive of neurodegeneration and death. For example,
cultured hippocampal neurons are spared from any which only selected neuronal populations are rendered
vulnerable by ubiquitously expressed mutant proteins,degenerative processes associated with mutant htt-
induced NIIs. The most remarkable feature is that only leading to the clinical and pathological presentations
that uniquely define each disorder.a subpopulation of striatal neurons that are invariably
lost in HD, the medium spiny, enkephalin-positive cells, How do polypeptides with polyglutamine expansions
translocate into the nucleus? For some molecules, theare most vulnerable in this cell culture paradigm. Neu-
ronal nuclei exhibited chromatin condensation, pyknosis, problem is simple; in the case of ataxin-1, and ataxin-7
(expanded in SCA7), nuclear translocation is certainlyand nuclear fragmentation, features consistent with
apoptosis; coexpression of BclXL completely blocked mediated by nuclear localization/import signals, while
the androgen receptor, expanded in SBMA, enters thethe process, as did extracellular addition of the caspase
CPP32 inhibitor, Ac-DEVD-CHO. Interestingly, and of nucleus after binding androgen. For others, including
htt, the story is still unfolding (no pun intended, seepotentially therapeutic value, brain-derived neurotrophic
factor (BDNF) and ciliary neurotrophic factor (CNTF) below). The prevailing model for htt, a large molecule
of z350 kDa normally localized to the cytoplasm, is thatcompletely protected against htt-induced apoptosis.
The novelty of the model aside, Saudou et al. have it is subject to proteolysis, resulting in an N-terminal
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fragment containing the glutamine expansions that sim- HDJ-2/HSDJ, a molecular chaperone, suppressed mutant
ataxin-1-mediated nuclear aggregates in transfectedply ªdiffusesº through the nuclear pore into the nucleus
where it aggregates. Indeed, NIIs are only detected im- HeLa cells (Cummings et al., 1988). In the context of the
model advanced by Saudou et al., we eagerly await themunocytochemically with antibodies to the N terminus
of htt, consistent with Western blot analysis of nuclear results of efforts to examine whether overexpression of
molecular chaperones in cultured striatal neurons orfractions from juvenile-onset HD cases, that reveal the
accumulation of an N-terminal, z40 kDa species (DiFig- Purkinje cells influence toxicity mediated by mutant htt
or ataxin-1, respectively.lia et al., 1997). Curiously, these nuclear fractions also
contain detectable levels of apparently ªfull-lengthº htt, The molecular and cellular basis for the differential
vulnerability of selected neuronal populations in eachspecies not observed in nuclear fractions prepared from
control brains. These studies beg the question of polyglutamine expansion disorder is poorly understood,
and hence, the comments that follow should only bewhether the polyglutamine expansions might induce
conformational changes that effectively ªunmaskº a viewed as provocative. At a first approximation, selectiv-
ity probably involves the interaction of mutant proteinsfunctional NLS in htt or expose a protein association
domain that interacts with polypeptides normally des- with cell-specific factors. A case in point is the inter-
action of ataxin-1 with LANP, a protein abundant intined for the nucleus (a ªpiggy-backº model). In regard
to the former suggestion, htt contains a patch of basic Purkinje cell nuclei (Matilla et al. 1997). Similarly, novel
protein±protein interactions might be enhanced by in-residues in the amino terminus, homologous to the NLS
sequence in the protein encoded by the familial breast creasing the number of conformational states adopted
by each polyglutamine expanded polypeptide. In thiscancer gene BRCA1. Consistent with the notion that
polyglutamine expansions induce conformational alter- case, the number of conformational states might be
dictated by the relative levels or composition of molecu-ations in htt (and for that matter, in other CAG expansion
disorders as well), polyglutamine expansions can be lar chaperones in individual neurons. It does seem coin-
cidental that a short amino-terminal fragment enricheduniquely identified, in a length-dependent manner, by a
particular monoclonal antibody (Trottier et al., 1995). in glutamine and asparagine residues is required for
maintenance of the prion-like properties of yeast Sup35p,Additionally, the htt-interacting proteins HAP-1 and
SH3GL3 exhibit enhanced binding to htt with expanded and that the chaperone Hsp104 has a pivotal role in this
process (for review, see Lindquist, 1997).polyglutamines (Li et al., 1995; Sittler et al., 1998 [Octo-
ber issue of Molecular Cell]). SH3GL3, a novel SH3- Inclusions and Toxicity: Genetic Models
The aforementioned cell culture and transgenic modelscontaining Grb2-like protein, promoted formation of in-
soluble polyglutamine aggregates in cultured cells that have been enormously useful for dissecting domains
essential for the pathogenicity of proteins with polyglu-coexpress htt encoded by the first exon and 52 gluta-
mines. Equally conceivable is that htt with polyglutamine tamine expansions. Added to these efforts, are two re-
cent reports in which aspects of polyglutamine-medi-expansions might be imported into the nucleus by path-
ways other than the ªclassicalº karyopherin a/b path- ated neurodegeneration have been recapitulated in D.
melanogaster neurons. In these studies, Bonini and col-way, which involves binding and delivery of substrates
with NLS sequences to the nuclear pore complex (NPC). leagues (Warrick et al., 1998) and Zipurski and coworkers
(Jackson et al., 1998 [September issue of Neuron]) haveIt is now clear that there is a superfamily of b karyopher-
ins and that some function on their own in docking expressed polyglutamine-expanded, truncated forms of
ataxin-3 (mutated in MJD) or htt, respectively, in photo-substrates to the NPC, without the need for an a kary-
opherin adaptor (reviewed in Pemberton et al., 1998). receptor neurons of D. melanogaster. In both instances,
expression of the mutant proteins cause retinal degener-These alternatives can be readily addressed in reconsti-
tution paradigms involving mammalian permeabilized ation and cell death. In the studies by Jackson et al.,
the age of onset and severity of neuronal degeneration ofcell systems and Xenopus oocyte injections.
Once in the nucleus, how do the polypeptides with adult photoreceptors was correlated with repeat length,
and nuclear localization of truncated htt presaged neu-polyglutamine repeats aggregate to form NIIs? Perutz
and colleagues first proposed that the glutamine repeats ronal degeneration. One can envision gain- and loss-of-
function genetic modifier screens in these systems toact as polar zippers that join complementary proteins,
resulting in precipitation (Perutz et al., 1994). In the case identify factors that influence nuclear localization and
pathogenicity of proteins with polyglutamine expansions.of mutant ataxin-1, it has been firmly established that
components of the nuclear matrix, including the cerebel- Conclusions
In just over a year, a wealth of information has emergedlar leucine-rich acidic nuclear protein (LANP) and promy-
elocytic leukemia protein, ªprecipitateº in NIIs (Matilla et relevent to the pathogenic mechanisms underlying tri-
nucleotide expansion disorders. We all recall the egre-al., 1997; Skinner et al., 1997). Despite these compelling
studies, the significance of these observations to ataxin- gious claims made by the news media upon the provoca-
tive discovery of intranuclear inclusions in neurons of1-induced pathology now seem moot when placed in
the context of the recent studies by Klement et al. and transgenic mice and humans expressing mutant pro-
teins with polyglutamine expansions. The exciting newSaudou et al. Assuming that the conclusions drawn by
Saudou et al. are generalizable to the entire spectrum findings by Klement et al. and Saudou et al. now leave
the field to ponder the physiological significance ofof polyglutamine expansion disorders, strategies to
forestall formation, or promote dissassembly, of nuclear the inclusions. Nuclear translocation of polyglutamine-
expanded proteins seems sufficient to initiate pathogen-aggregates may prove deleterious. In this regard, Zoghbi
and colleagues have reported that overexpression of esis. Yet to be defined, however, are the mechanisms
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of nuclear translocation (at least for huntingtin and the
DRPLA-associated atrophin-1) and the cell-specific sig-
naling mechanisms that drive pathogenesis. Neverthe-
less, the advent of powerful in vitro neuronal cell culture
paradigms and Drosophila models should prove enor-
mously useful for clarifying these complex issues. More
importantly, identification of molecular targets involved
in these processes offers opportunities for the develop-
ment of rational therapeutic strategies aimed at pre-
venting or ameliorating the devastating clinical manifes-
tations and neurodegenerative processes associated
with polyglutamine expansion disorders.
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